Search for: "Matter of Noonan"
Results 81 - 100
of 302
Sorted by Relevance
|
Sort by Date
21 May 2018, 9:46 pm
Noonan -- Last week, the Federal Circuit found all patent claims invalid for obviousness in an inter partes review, in Praxair Distribution, Inc. v. [read post]
20 Aug 2015, 9:08 pm
Noonan -- In the 1977 Yale Law School Holiday Pageant there was a skit about the Supreme Court, with a song sung to the tune of Cole Porter's "Another Opening, Another Show" from the musical Kiss Me Kate: Another opening, another term A chance to show that no precedent's firm Another opening of another term That parody irresistibly comes to mind with many of the Supreme Court's patent decisions (no matter how hard the Court appears to want to create the… [read post]
7 Oct 2018, 9:33 pm
MBHB attorneys and Patent Docs authors Kevin Noonan and Donald Zuhn, and MBHB attorneys Josh Rich, Lisa Hillman, Sarah Fendrick, John Conour, and Nate Chongsiriwatana will provide presentations on the following topics: • Updates on Subject Matter Eligibility Analysis • Patenting Repurposed Drugs • Antibody Patenting after Amgen v. [read post]
7 Nov 2021, 9:50 pm
In the webinar, entitled "Accepting the Status Quo: Subject Matter Eligibility Nearly a Decade after Mayo," Kevin Noonan and Donald Zuhn Jr. of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Cara Coburn of Genentech, June Cohan of the U.S. [read post]
28 Apr 2014, 9:51 pm
These patents were commonly owned, named the same inventors, and were directed to related subject matter (interference with viruses... [read post]
26 Dec 2017, 9:54 pm
Noonan -- Great cases like hard cases make bad law. [read post]
18 Oct 2011, 9:54 pm
Noonan -- The European Court of Justice (ECJ) today rendered its decision regarding the patent-eligibility of human embryonic stem cells (hESCs) in Europe, and as widely expected has heeded the recommendation of the court's advocate general that hESCs are not patent-eligible subject matter (see "European Court of Justice Considers Embryonic Stem Cell Ban"). [read post]
26 Jul 2022, 9:30 pm
Noonan -- Kathi Vidal, Under Secretary of Commerce for Intellectual Property and Director of the U.S. [read post]
12 Sep 2018, 9:13 pm
MBHB attorneys and Patent Docs authors Kevin Noonan and Donald Zuhn, and MBHB attorneys Lisa Hillman, Sarah Fendrick, James DeGiulio, John Conour, and Nate Chongsiriwatana will provide presentations on the following topics: • Updates on Subject Matter Eligibility Analysis • Patenting Repurposed Drugs • Antibody Patenting after Amgen v. [read post]
19 Mar 2020, 9:55 pm
From the first sentence, the petition frames the issue as one of lower court confusion with the Supreme Court's subject matter eligibility jurisprudence: In the years since this Court's decision in Mayo Collaborative Services LLC v. [read post]
28 Nov 2021, 9:14 pm
Noonan -- The Leahy-Smith America Invents Act prescribed two very different post-grant review proceedings in U.S. patent law. [read post]
30 Jun 2014, 9:59 pm
Noonan -- Sounding an appropriately alarmist note, Bloomberg BNA has issued the results of a study on how the U.S. [read post]
23 Sep 2018, 12:15 pm
MBHB attorneys and Patent Docs authors Kevin Noonan and Donald Zuhn, and MBHB attorneys Josh Rich, Lisa Hillman, Sarah Fendrick, John Conour, and Nate Chongsiriwatana will provide presentations on the following topics: • Updates on Subject Matter Eligibility Analysis • Patenting Repurposed Drugs • Antibody Patenting after Amgen v. [read post]
20 Apr 2023, 8:46 pm
Noonan -- An appellant's burden on appeal is never easy but it is particularly difficult when the questions at issue are based on factual evidence. [read post]
7 Nov 2021, 9:50 pm
In the webinar, entitled "Accepting the Status Quo: Subject Matter Eligibility Nearly a Decade after Mayo," Kevin Noonan and Donald Zuhn Jr. of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Cara Coburn of Genentech, June Cohan of the U.S. [read post]
22 Dec 2021, 8:51 pm
Noonan -- The issue of standing can be outcome-determinative: without it, no matter how worthy a party's position or arguments, a court will not consider them without standing. [read post]
16 Feb 2015, 9:59 pm
The one remaining matter, Myriad's case against GeneDx has settled, as announced by the company today. [read post]
25 Oct 2020, 9:44 pm
Noonan -- One of the most interesting (albeit troubling) decisions by the Federal Circuit in the past year or so was its decisions, by a panel and then in denying review en banc, in American Axle & Manufacturing, Inc. v. [read post]
29 Mar 2017, 9:59 pm
Supreme Court decisions interpreting (and seriously revising) the scope of subject matter eligibility. [read post]
20 May 2021, 9:14 pm
The matter arose when Pacific Biosciences asserted U.S. [read post]
